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Abstract
Background: Withdrawal of disease-modifying anti-rheumatic drugs (DMARDs) once disease remission is achieved
is endorsed by current international rheumatoid arthritis (RA) management guidelines. However, very little data
exists concerning patients’ views of this practice. In this qualitative study, we aimed to explore patients’
perspectives on DMARD withdrawal in the setting of established RA.
Methods: In this qualitative interview study, patients with stable established RA were recruited from rheumatology
outpatient clinics at a large UK teaching hospital. The perceived advantages and disadvantages of DMARDs and views
on DMARD withdrawal were explored in semi-structured interviews. Interview transcripts were analysed using standard
qualitative techniques to construct an analytical framework.
Results: Thirteen participants (8 female, median [IQR] age 65 [61–73]) expressed their views of DMARD treatment in
the context of their “normal lives”. For some patients, disadvantages such as medication side-effects and the
inconvenience of safety monitoring were sufficient hindrances to their lifestyle to justify DMARD withdrawal.
However, patients who were vulnerable to loss of physical function, or who had prior experience of severe
rheumatoid arthritis, expressed a strong preference against DMARD withdrawal, viewing the potential for
increased pain and future disability as unacceptable risks.
Conclusions: Patients view DMARD withdrawal in the context of either restoring or threatening their “normal
lives”. In this model, social and personal factors play a crucial role in influencing patients’ opinions of DMARD
therapy beyond a simple consideration of medication side-effects alone. A formulaic approach to DMARD
withdrawal determined and imposed by clinicians would not be successful. Instead, the discussion of DMARD
withdrawal should take place with the identification of patients’ priorities and in the context of their personal
disease experiences.
Trial registration: clinicaltrials.gov (NCT02064400), retrospectively registered 17 February 2014.
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Background
The traditional view of rheumatoid arthritis (RA) as a
chronic destructive arthritis where pain, stiffness and
disability are inevitable for all patients is now obsolete.
Remission is now a realistic target of treatment for many
patients through the use of modern disease modifying
anti-rheumatic drugs (DMARDs), particularly when used
in combination and early in the course of the disease [1].
Nevertheless, the use of DMARDs is associated with sig-
nificant burdens including the risk of toxicity and the in-
convenience posed by regular dosing and monitoring
schedules [2]. With significant numbers of patients now
achieving remission, patients and their clinicians are in-
creasingly faced with a therapeutic conundrum: when is
it appropriate to withdraw DMARD therapy once remis-
sion is achieved?
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It is important to recognise the dilemma facing pa-
tients when confronted with the prospect of DMARD
withdrawal. Several studies have explored patients’ be-
liefs and experiences surrounding DMARD therapy in
RA and the crucial effects of these upon medication ad-
herence [3–6]. Much has also been published on the
topic of normalisation in long-term disease – originally
described by Strauss and Glaser [7], and more recently
defined by Morse et al. [8] as the “strategies designed
to minimise the impact of (or accommodate) an ill-
ness or related disability or both”. However, there is a
paucity of studies that have addressed the importance
of patients’ opinions and concerns regarding the deci-
sion to withdraw DMARD therapy once remission
has been achieved.
Longitudinal cohort data in early RA suggest that up
to 15% of all patients can achieve DMARD-free remis-
sion [9], with prospective clinical trials demonstrating
maintenance of remission in up to half of patients after
complete withdrawal of DMARD therapy [10, 11], albeit
at the risk of disease flare. [12] Guidelines from the
European League Against Rheumatism [13] and Ameri-
can College of Rheumatology [14] support the concept
of DMARD withdrawal for patients with RA who
achieve remission. Nevertheless, considerable uncer-
tainty exists, not least due to the absence of robust bio-
markers of remission and a lack of consensus regarding
the optimal strategy for DMARD withdrawal [15, 16].
In this study we present an analysis of the issues
surrounding DMARD withdrawal from the patient
perspective. Through the use of semi-structured inter-
views we aimed to identify the perceived advantages
and disadvantages of DMARD therapy, and the extent
to which these and other factors influence patients’
opinions of DMARD withdrawal.
Methods
Study design
We conducted a qualitative study of patients’ views on
DMARD therapy and DMARD withdrawal using semi-
structured interviews. The study was designed to assess
the feasibility of a future clinical trial of DMARD with-
drawal, and to inform the consent and counselling
process required.
Participants
Patients were consecutively recruited to the study from
routine outpatient clinic attendances face-to-face by
their rheumatology clinician in a single UK hospital. Eli-
gible patients were identified as those who had a clinical
diagnosis of RA controlled by DMARDs, with symptom
onset at least 12 months previously and stable disease
defined as no change in DMARD therapy or use of cor-
ticosteroids in the previous 6 months before recruitment.
No patients receiving biologic therapy had been re-
cruited after the first 10 interviews, and thus protocol-
specified purposive sampling [17] was used to specific-
ally recruit additional patients receiving biologic agents.
Study recruitment was stopped when saturation [18] of
themes was reached after 13 patients (i.e. when no new
themes emerged from consecutive interview analyses),
reflecting the anticipated target of 10–15 interviews as
specified in the study protocol.
All patients were assessed for joint pain and swelling
on the day of interview by the same clinician (KB). This
was combined with their most recent erythrocyte sedi-
mentation rate (ESR) measurement to calculate their
Disease Activity Score in 28 Joints (DAS28) [19]. A
retrospective clinical notes review was conducted to as-
sess cumulative fulfilment of the 2010 American College
of Rheumatology/European League Against Rheumatism
(ACR/EULAR) diagnostic criteria for RA [20], with all
but one patient (Patient M) satisfying these criteria.
Nevertheless, this patient had a clinical diagnosis of
established RA confirmed by a consultant rheumatolo-
gist and had received long-term DMARD therapy, and
thus satisfied our study inclusion criteria.
Data collection
Semi-structured patient interviews (‘Patient interview
schedule’, online Additional file 1) were developed to ad-
dress two broad areas, namely: 1) the benefits, negative
aspects and concerns surrounding DMARD therapy, and
2) views of patients concerning complete DMARD with-
drawal within a clinical research setting (the latter of
which to inform future clinical trial design). Interviews
were conducted by the same researcher (KB) in a private
rheumatology outpatient consulting room. Following a
consent process and explanation of the interview format,
patients were asked to discuss advantages and disadvan-
tages of DMARD therapy and opinions regarding theor-
etical DMARD withdrawal in the setting of the
aforementioned future clinical trial. Interview schedule
questions were used as initial prompts for discussion,
with patients encouraged to raise and discuss more
widely the issues relevant to their own personal circum-
stances and experiences.
Data analysis
Audiotape recordings of a median (range) duration of 15.2
(7.9 to 27) minutes were transcribed verbatim using con-
versation notation [21]. In a qualitative content analysis
approach, [22] transcripts were analysed and coded line-
by-line by KB and BT, and coding practices reviewed and
agreed. Interview themes were explored by KB/BT using
standard qualitative techniques including constant com-
parison, deviant case analysis and memoing to create an
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analytical framework (Additional file 2: Figure S1 and
Additional file 3: Figure S2, online Additional files).
Rigor and accuracy of the qualitative study
KB is a male rheumatology clinical researcher with ex-
perience in the diagnosis and management of RA, who
designed and conducted the study as part of a super-
vised Masters degree. BT is a male rheumatology con-
sultant with extensive experience of qualitative research
including his own qualitative MD research degree, and
supervision of qualitative research studies at Masters,
Doctoral and post-Doctoral levels. Interview transcripts
were checked against the original audio recordings and
their accuracy verified by KB. Once the analytic frame-
work was developed, this was reviewed with reference to
the transcripts and agreed between all researchers. This
study adheres to the COREQ (COnsolidated criteria for
REporting Qualitative research) standards [23].
Ethical considerations
The study was approved by a research ethics committee
(National Research Ethics Service East of England –
Cambridge Central Research Ethics Committee [13/EE/
0459]). All patients provided written informed consent
before participation, which included permission to re-
produce anonymised verbatim quotations from interview
transcripts. Research was conducted in accordance with
the Declaration of Helsinki [24].
Results
Characteristics of patient cohort
Thirteen patients were interviewed over a three-
month period, the majority with established RA of
several years duration (Table 1). Methotrexate mono-
therapy was the most common DMARD regimen; 10/
13 patients achieved a DAS28 < 2.6 in keeping with
disease remission.
Advantages of DMARD therapy
Participants identified a wide range of advantages of re-
ceiving DMARD therapy (Table 2). In seven cases, these
centred on the alleviation of physical symptoms such as
pain, swelling and stiffness. For these patients, this was
seen as helping to maintain their everyday physical
function.
It [methotrexate and sulfasalazine] keeps you mobile,
you know? Your joints are flexible, you know, you’re
able to do things that you perhaps wouldn’t be able to,
you know? Just simple everyday things. (Patient A,
70-74 yrs., RA for 11 years).
The ability to keep performing daily physical acts was
often expressed in terms of “maintaining mobility”,
“keeping steady” and ultimately “living a normal life”. In
addition to permitting a ‘normal life’ through mainten-
ance of daily activities, four patients identified DMARDs
as restoring a holistic state of normality.
KB: What do you feel as the benefit to you of etanercept?
Pt D: Living a normal life. Mobility, everything really
that I couldn’t do when I had flare ups, which I don’t
have now. It enables me to walk without pain. To do
all activities without pain. A different way of life.
(Patient D, 65-69 yrs., RA for 14 years).
All patients could identify symptomatic and functional
benefits of DMARD therapy. However, five patients ap-
peared to have little expectation of DMARDs improving
their own current condition. Instead, DMARD therapy
was highly valued by these patients in terms of prevent-
ing future deterioration of their symptoms.
I don’t particularly feel there has been any correction
or improvement [with taking DMARDs]. But certainly
I feel no worse. So like a status quo. (Patient F, 60-64
yrs., RA for 3 years).
The fear of future symptom burden and physical dis-
ability was a strong recurring theme throughout the
interview process. In some cases this concern also ex-
tended to the possibility of future physical deformities,
recognised as both unsightly and limiting physical abil-
ity, and was a powerful motivation to continue DMARD
therapy.
I don’t wanna believe that, they [my joints] would be
deformed or owt like that, you know what I mean?
So, you know, if you can keep everything steady that’s
great for me. The last thing that I want is to be like I
have when I’ve like seized up in my fingers, and stuff
Table 1 Patient demographics and clinical details
Demographic / clinical data Value
Number of patients recruited 13
Female [%] 8 [53%]
Age: median [IQR, range] years 65 [61–73, 44–85]
Time since RA diagnosis: median [IQR] years 10 [3–13]
RhF and/or ACPA positive: n [%] 9 [69%]
Current use of methotrexate: n [%] 11 [85%]
Current use of hydroxychloroquine: n [%] 1 [8%]
Current use of sulfasalazine: n [%] 2 [15%]
Current use of biologics: n [%] 2 [15%]
DAS28: median [IQR] 1.56 [1.35–2.44]
ACPA: anti-citrullinated peptide antibody: IQR: interquartile range, RhF:
rheumatoid factor
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like that. So, if methotrexate can sort of prevent that,
I’m happy to take it. (Patient E, 40-44 yrs., RA for 1
year).
In summary, although a wide range of advantages
of DMARDs were identified by patients in our cohort,
these were framed within the context of their ability
to lead a “normal life”. Many patients were fearful of
future symptom burden and disability, which was
sufficient motivation to continue therapy even in the
absence of any short-term symptomatic relief or func-
tional improvement.
Disadvantages of DMARD therapy
The physical side-effects of medications were a strongly
cited disadvantage of DMARD therapy (Table 3), though
individual patients described different mechanisms to
deal with this potential threat. For some patients, the
balance of side-effects versus effective control of RA ap-
peared to be an important factor in the decision to com-
mence DMARD therapy. Thus for these patients, their
DMARD therapy represented a favourable balance of
benefit versus risk. However, five patients chose to over-
look the potential side-effects when taking DMARDs
and instead delegated this concern to another individual
such as their doctor or a family member.
Pt I: Me [colloq. My] son who has the same, said “Have
you read the leaflet? It causes terrible problems!” and I
said “Well I haven’t read the leaflet and it hasn’t caused
me any problems”. But he is like me husband, he reads
every little last detail on the leaflet.
KB: Yes, yes. Did you get a leaflet at the time?
Pt I: I did, yeah.
KB: Yes, yes. And why didn’t you want to read through
all of it? Was it because …
Pt I: Because I never do. I never read leaflets.
KB: Is that because it, because you find it …
Pt I: I think it would put you off. (Patient I, 75-79 yrs.,
RA for 13 years).
The need to attend extra appointments for blood
monitoring tests, order tablets from pharmacy and
difficulties in transporting medication abroad were prag-
matic disadvantages highlighted by six patients as inter-
fering with a “normal” lifestyle.
If I go on holiday, I’ve got to make sure that I have a
fridge where I go. I mean I’ve just been away, and it
[adalimumab dose] was in the middle of our holiday,
which was badly planned really. It’s just thinking of
ways to keep this injection at the right temperature.
(Patient J, 65-69 yrs., RA for 11 years).
Having to order prescriptions every month, you know,
go and collect them, put your tablets out every evening
for the next day (Patient A, 70–74 yrs., RA for 11
years).
In addition, one patient who received biologic therapy
also reported that DMARD therapy caused complica-
tions with their healthcare, particularly the management
of comorbidities by non-rheumatology specialists who
were unfamiliar with their DMARD therapy.
They’re not aware, you know, I don’t think that
anybody outside this field is aware of the type of
Table 2 The advantages and disadvantages of disease modifying anti-rheumatic drug (DMARD) therapy as perceived by patients
Advantages of DMARDs Disadvantages of DMARDs
Alleviation of physical symptoms of RA (i.e. pain, swelling and stiffness) Side-effects of medication
Maintain mobility:
1. For everyday physical functions
2. For employment
Practical issues with taking medication:
1. Extra appointments for blood monitoring tests
2. Ordering and taking tablets
3. Difficulties in transporting medication abroad
Prevent future deterioration and deformity Complication of healthcare provided by non-rheumatology specialists
Table 3 Summary of the side effects of disease modifying anti-rheumatic drug (DMARD) therapy identified by patients within the
study
Organ system Side-effect
Gastrointestinal Nausea, vomiting, heartburn, hepatitis, bowel disturbance
Skin Rash, bruising, stinging at injection site (biologics), hair loss
General health Fatigue, mood swings, weight gain
Miscellaneous Increased infection risk, blood cell abnormalities, change in urine colour, possible increased cancer risk
Baker et al. BMC Rheumatology             (2019) 3:2 Page 4 of 8
medication you take, really. (Patient J, 65-69 yrs., RA
for 11 years).
In summary, patients could identify disadvantages to
DMARDs in terms of barriers to their “normal” lifestyle
and physical side-effects. For some patients (exemplified
by the quotations from patients F & E above), the risk of
continued symptoms, physical limitation and joint de-
formities were viewed as sufficient to justify DMARD
therapy despite the potential disadvantages. In contrast,
others (such as patient I above) chose to overlook the
potential risks and focus exclusively upon the benefits of
treatment as a means to justify DMARD therapy.
DMARD withdrawal
Patients could relate to the dilemma of DMARD with-
drawal in the setting of remission and the uncertainty
that this poses.
‘Cause you wonder if you keep on taking stuff like,
whether, it’s, you’re just taking it, and would you be
alright without it, you know? You, you don’t know,
because you just keep taking it all the time. (Patient J,
65-69 yrs., RA for 11 years).
Patients generally expressed a desire to reduce their
medication, driven by concerns regarding the potential
toxicity of long-term DMARD therapy. Nevertheless,
these concerns tended not to focus on specific side-
effects but instead as an ill-defined notion of DMARDs
as deleterious to health. Two patients believed this effect
to be cumulative and specific to long-term DMARD use,
and hence recognised DMARD withdrawal as advanta-
geous in limiting this effect.
I don’t know what the long term, if any long-term side
effects happen with this I’ve no idea, you know, not
that I remember anyway. It’s always better to stop
something if you don’t need it. (Patient H, 55-59 yrs.,
RA for 1 year).
KB: What would be the benefits for you do you think
of stopping methotrexate?
Pt K: I think, just less toxicity for your body really isn’t
it? (Patient K, 50-54 yrs., RA for 10 years).
In addition, patients could also identify further benefits
of DMARD withdrawal in terms of restoring a degree of
normality to their lifestyle. A strong recurring theme
throughout the interviews was a desire to reduce the
burden of prescribed medication, which was viewed as a
substantial benefit in its own right.
Pt C: I would love to come off them. I would love to
come off all the tablets that I’m on.
KB: And, and what would your reasons be for wanting
to come off of methotrexate?
Pt C: Just because I’m sick of taking tablets. (Patient C,
85-89 yrs., RA for 2 years).
For four patients, the DMARD dosing and monitoring
schedules posed a substantial barrier to their lifestyle.
For these patients, DMARD withdrawal offered a means
by which they could achieve a freedom from the con-
straints of DMARD monitoring and hence live a more
“normal life”.
Every now and then I go away for a reasonably longer
period because I’m retired now. So I can go away for two
or three months for example. So, I’m stopped from doing
that because of having to consider this blood monitoring
situation. And then, I cannot go away more than 6, 7
weeks. Okay? And it would have to coincide with this
gap, this window, which is due to blood monitoring tests.
If … I was able to do without the medication for
a longer period, then that may give you back that
freedom. (Patient F, 60-64 yrs., RA for 3 years).
The majority (9/13) of patients who were interviewed
would consider withdrawal of DMARD therapy, al-
though four patients would never consider stopping
DMARD treatment. Particularly important amongst this
group was their prior experience of RA. Personal experi-
ence of previously difficult-to-control or severe RA was
a strong disincentive to discontinue DMARDs. Further-
more, experience of friends or family with severe and
deforming RA was also a strong factor against DMARD
cessation. For one patient (Patient M), the act of taking
DMARDs was seen as a positive control mechanism that
could be used to prevent future deterioration of their
RA. For this patient, the prospect of DMARD with-
drawal represented a loss of control over their disease
with consequent worry of future irreversible joint dam-
age, reinforced by the severe RA they had witnessed
within their own family.
Pt M: I think it’s reassuring when you’re actually doing
something, when you’ve got a history of it [RA] in the
family and you know how worse it can get. I don’t
want to get to that point where, I’m just, you know
allowing it to progress.
KB: Right. So it’s actually sort of, taking the tablet
almost feels like you are doing something to help
control things?
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Pt M: Yes. So to come off of it would be worrying.
(Patient M, 60-64 yrs., RA for 5 years).
In addition, patients also considered the consequences
of a deterioration in RA control in terms of their indi-
vidual social circumstances when contemplating
DMARD withdrawal, with those in current employment
or with dependent others attributing greater importance
to this.
My main concern [about stopping DMARDs] is
obviously if my symptoms are sort of untreated though,
and continued. I don’t want to get deformities, other
than what I’ve got at the minute. It could affect my job
dramatically, bearing in mind we’ve all got to work
longer. You know, it’s pretty hard to hold a saw or a
hammer if your fingers are pointing in all directions.
(Patient E, 40-44 yrs., RA for 1 year).
In summary, patients expressed a strong desire to re-
duce their DMARD medication, driven by the hindrance
it places upon their “normal” lifestyle and concerns re-
garding its potential toxicity. Nevertheless, the threat of
loss of control of RA activity upon DMARD withdrawal
was also considered and was prioritised by those with
previous experience of severe RA or vulnerability to loss
of physical function. A summary of the issues identified
in the patient interviews surrounding DMARD cessation
is presented in Table 4.
Discussion
The patients within this study expressed views of
DMARD therapy in terms of either enablement or hin-
drance of their daily routine and ability to live a “normal
life”, a strong theme in our analysis. One strategy of nor-
malisation is to downgrade expectations of a “normal”
state, illustrated by the relatively modest definitions of
normality described by many patients in this study – to
walk and wash oneself without pain, for example. Never-
theless, medication represents an important tool to
reduce the burden of living with RA; indeed, minimisa-
tion of the personal impact of RA and a return to nor-
mality have been demonstrated to be central priorities in
recent studies of patient-reported expectations of
DMARD therapy [25] and RA remission [26].
These patients with established RA identified advan-
tages of DMARD therapy in terms of reduced symp-
toms, maintenance of mobility or prevention of future
deterioration. Nevertheless, the same patients also
recognised disadvantages to DMARD therapy including
medication side-effects, blood safety monitoring and the
practicalities of taking regular medication. This range of
views regarding DMARD therapy is comparable to pre-
vious studies of patient views of long-term DMARD
therapy in RA [4, 5].
A notable recurring theme in our study was a strong
desire of many patients to reduce the amount of medica-
tion they received. Indeed, a preference towards drug
minimisation has been described previously in studies of
long-term illness both within and outside the setting of
RA [4]. For many patients in this study, a preference to-
wards DMARD withdrawal was underpinned by concern
regarding the potential long-term toxicity of DMARDs.
Nevertheless, several patients in our study overlooked
these potential side-effects yet still favoured DMARD
withdrawal, supported by a wider consideration of the
impact of DMARD therapy upon their individual lives.
Indeed, in a recent study of patients’ views of DMARD
escalation in RA, additional personal and sociodemo-
graphic factors such as current employment and caring
roles were found to play a crucial role in the decision-
making process beyond a simple consideration of medi-
cation side-effect profile [27].
In a previous qualitative study of 20 patients with RA,
Markusse et al. [28] observed a range of both positive
and negative emotions of patients when considering the
prospect of DMARD withdrawal. Many of these emo-
tions paralleled those expressed by patients in our study
and included happiness and relief at avoiding regular
medication tempered by fear of the return of RA
Table 4 Overview of the themes arising from patient interviews surrounding potential withdrawal of disease-modifying anti-
rheumatic drug (DMARD) therapy
Theme Comments
Uncertainty after DMARD withdrawal Uncertainty and unpredictability of developing flare of RA after DMARD withdrawal
Getting rid of unnecessary medication Benefits of stopping “unnecessary medication” in terms of avoidance of toxicity and the
need for blood monitoring
Feeling of loss of control over disease DMARDs as a “weapon” that fights disease, without which patients feel a loss of control
over their RA
Previous disease experiences Personal or family/friend experience of treatment-resistant or deforming RA is a strong
disincentive to DMARD withdrawal
Social circumstances Patient less likely to consider DMARD withdrawal if their social circumstances make them
vulnerable to disease flare and periods of reduced physical function – e.g. caring for
dependent family member, manual worker.
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symptoms and arthritis progression. An analysis of
the impact of previous disease experiences and social
circumstances was not included, although our study
also suggests that these are important additional fac-
tors that can crucially influence patients’ views of
DMARD withdrawal.
Based upon the results of our study, we propose a
framework whereby patients consider the impact of
DMARD withdrawal in the context of either facilitating
or hindering their “normal life”. For many patients, the
disadvantages of DMARD therapy pose significant life-
style hindrances and support a preference towards
DMARD withdrawal. Nevertheless, for some patients
the risk of deterioration in their RA due to medication
withdrawal is sufficient motivation to continue DMARD
therapy. Crucially, patients who are vulnerable to loss of
physical function – for example, by virtue of their em-
ployment or dependent others – or who have previous
experience of severe RA, prioritise this risk and thus
favoured DMARD continuation. Furthermore, it is im-
portant to note that all of the patients in this study
expressed a clear preference either for or against
DMARD withdrawal. This highlights the importance of
an individualised approach when addressing the issue of
DMARD minimisation, and suggests that simple deci-
sion pathways driven by assessments of disease activity
alone would not be successful.
There are several limitations to this study, not least
that participants were asked to discuss their views of a
theoretical withdrawal of DMARD therapy in a research
environment, which may differ from their actions in
practice. The interview duration was relatively short,
and it is possible that longer discussions may have iden-
tified additional more complex themes. Furthermore, pa-
tients in this study were specifically asked to discuss
stopping DMARD therapy in relation to a proposed fu-
ture trial of complete DMARD withdrawal, and may
have responded differently if asked to consider partial ta-
pering of therapy. Nevertheless, we believe the issues
raised are of relevance to clinicians and patients in the
setting of both withdrawal and tapering of treatment.
The limited ethnic diversity of patients attending our
rheumatology department, combined with the relatively
advanced age of the study cohort, may affect the gener-
alisability of the results to other populations. Further-
more, interviewing by a clinician in a hospital setting
may have influenced the range of opinions expressed by
participants who may be less willing to express opinions
contrary to those of their rheumatology team. [23] This
study was a pilot study to inform the design of an
imminent future clinical trial of DMARD withdrawal – a
further additional pilot of this study was not performed,
though it is possible that this may have helped to further
refine the methodology and analyses presented herein.
Conclusions
With the significant rates of remission in RA observed
with modern DMARD therapy, the question of when
and how to reduce the burden of immunosuppressive
medication in this group of patients is of increasing im-
portance. The withdrawal of DMARDs represents the
later stages of what can often be a long and challenging
illness journey, with patients’ opinions heavily influenced
not only by their current personal circumstances but
also by their previous experiences. Our study offers this
unique insight in order to help clinicians address pa-
tients’ concerns in this fundamentally individualised and
shared decision-making process.
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